A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and
subcutaneous (SC) doses in men and women with progressive multiple sclerosis.
Secondary Objectives:
To assess the following in men and women with progressive multiple sclerosis:
- The pharmacokinetic (PK) parameters of GZ402668 after ascending single IV doses.
- The pharmacodynamics (PD) of GZ402668 after ascending single IV doses.
- The PK parameters of GZ402668 after ascending single SC doses.
- The PD of GZ402668 after ascending single SC doses.